Factor 11 Inhibitors as Next-Generation Anticoagulants

Factor XI inhibitors are a new class of anticoagulant drugs designed to prevent blood clots by targeting a single protein in the clotting cascade, factor XI, that appears to drive dangerous clot formation while playing only a minor role in the everyday wound-healing type of clotting your body depends on. That distinction is why researchers have spent over a decade pursuing these drugs: they hold the promise of preventing strokes, deep vein clots, and other thrombotic events without the bleeding risk that shadows every existing blood thinner. Several candidates are now in late-stage clinical trials, and the results so far reveal both striking successes and a sobering setback that has reshaped the field’s expectations.

Why Factor XI Is an Appealing Drug Target

Blood clotting is not a single switch but a chain reaction involving dozens of proteins. Factor XI sits in what’s called the intrinsic pathway, a branch of the cascade that amplifies clot formation once it has already started. Preclinical work in animal models showed that removing factor XI or factor XII from the equation greatly reduced the formation of the dangerous, vessel-blocking clots that cause strokes and pulmonary embolisms, yet it did not impair the protective clotting that stops a cut from bleeding indefinitely.¹ That observation suggested something genuinely new in anticoagulation: you might be able to uncouple thrombosis from hemostasis, keeping the dangerous clots at bay while leaving wound healing largely intact.²

The animal data were compelling, but what really built confidence was the human genetic evidence. A natural experiment has been running for generations among people born with factor XI deficiency, a condition most common in Ashkenazi Jewish populations but found worldwide. These individuals tend to have a modestly higher risk of bleeding after trauma or surgery, but they appear substantially protected against cardiovascular disease and venous clots. One large study found that people with low factor XI activity had roughly half the rate of heart attacks and strokes compared to people with normal levels, and their risk of venous thromboembolism was even lower.³ A separate study of people with severe factor XI deficiency found a dramatically reduced rate of ischemic stroke, about one-eighth of what would be expected based on their other risk factors, though interestingly, heart attack rates were similar to the general population.⁴

The bleeding side of the ledger, however, is not zero. A population study tracking people with any degree of factor XI deficiency found they had roughly two and a half times the risk of severe bleeding episodes compared to the general population, along with a moderately elevated risk of clinically relevant non-severe bleeding.⁵ So the protection against clots is not cost-free, but the bleeding risk is far lower than what you would see with deficiencies of other clotting factors. That profile made factor XI a rational and attractive target for drug development.

Types of Factor XI Inhibitors in Development

Drug companies have attacked factor XI from several different angles, and the variety of approaches is one of the more unusual features of this drug class. There are currently four main strategies in clinical testing:

Small-molecule inhibitors: Asundexian (Bayer) and milvexian (Bristol Myers Squibb/Janssen) are oral pills that block the active form of factor XI, called factor XIa, at its catalytic site. They work quickly, can be taken once or twice daily, and wear off within hours of the last dose.⁶
Monoclonal antibodies: Abelacimab (Anthos Therapeutics) and osocimab (Bayer) are injectable antibodies. Abelacimab is unusual in that it locks factor XI in an inactive shape, blocking both the inactive form and the already-activated form.⁷ Because antibodies last a long time in the body, abelacimab is given as a monthly injection.
Antisense oligonucleotides: Fesomersen (Ionis/Bayer) does not block factor XI directly. Instead, it instructs the liver to stop making the protein altogether, reducing circulating factor XI levels in a dose-dependent way over weeks.⁸ It is also given by injection, typically once a month.

Each approach has trade-offs. The small molecules are convenient pills and wear off fast, which is an advantage if a patient needs emergency surgery. The antibodies and antisense drugs provide steadier, more complete factor XI suppression, but their long duration of action makes them harder to reverse quickly. Those differences matter a great deal depending on the clinical setting, as the trial results have made clear.

Preventing Blood Clots After Joint Surgery

Orthopedic surgery, especially total knee replacement, is one of the highest-risk settings for venous blood clots. It is also the area where factor XI inhibitors have shown their most cleanly positive results. In a phase 2 trial, patients receiving milvexian twice daily after knee arthroplasty saw venous thromboembolism rates drop in a dose-dependent pattern, from about 21% at the lowest dose down to 8% at the highest, compared with 21% for the standard-of-care blood thinner enoxaparin. Bleeding rates were essentially the same as enoxaparin across all milvexian doses.⁹

A systematic review pooling data from multiple orthopedic trials reinforced this picture. Factor XI inhibitors as a group cut total venous thromboembolism roughly in half compared with standard low-molecular-weight heparin, while also lowering the rate of major or clinically relevant bleeding.¹⁰ Based on these results, two pivotal phase 3 trials are underway in the orthopedic setting.¹¹

Secondary Stroke Prevention

For people who have already had a non-cardioembolic stroke or transient ischemic attack (the kind not caused by atrial fibrillation), the question is whether adding a factor XIa inhibitor to standard antiplatelet therapy can reduce the chance of another stroke without causing dangerous bleeding. The phase 2 results were mixed: the PACIFIC-Stroke trial of asundexian showed no reduction in the composite of covert brain infarction or ischemic stroke at any dose tested.¹² A parallel phase 2 trial of milvexian (AXIOMATIC-SSP) also failed to find a significant dose-response relationship for stroke prevention, though it confirmed that adding milvexian did not meaningfully increase major bleeding.¹³

The larger phase 3 trial, however, told a different story. In OCEANIC-STROKE, over 12,000 patients were randomized to asundexian or placebo on top of antiplatelet therapy. Ischemic stroke occurred in about 6% of the asundexian group versus roughly 8% of the placebo group, a statistically significant reduction. Major bleeding was similar between the two arms.¹⁴ A meta-analysis of the stroke-prevention trials confirmed the overall conclusion: adding a factor XIa inhibitor to antiplatelet therapy after a non-cardioembolic stroke reduced recurrent stroke without an apparent increase in bleeding.¹⁵ This is a genuinely new finding, because existing blood thinners have generally been too risky for routine use in this patient group.

The Atrial Fibrillation Setback

Atrial fibrillation was supposed to be the biggest commercial prize for factor XI inhibitors. Millions of people with this heart rhythm disorder take blood thinners like apixaban or rivaroxaban to prevent stroke, and many of them experience bleeding complications. A drug that could match the stroke prevention of these direct oral anticoagulants (DOACs) while causing far less bleeding would be transformative. Early phase 2 data were encouraging on the bleeding front: in one trial, asundexian reduced clinically relevant bleeding by roughly half to more than 80% compared to apixaban.¹⁶

Then came OCEANIC-AF, the only completed phase 3 trial of a factor XI inhibitor in atrial fibrillation. This massive study randomized nearly 15,000 patients with high-risk AF to asundexian or apixaban. It was stopped early on the recommendation of an independent monitoring committee because asundexian clearly failed. Ischemic stroke and systemic embolism occurred at a rate of 1.3% with asundexian versus 0.4% with apixaban, meaning patients on the experimental drug had about a fourfold higher rate of these events.¹⁷ A meta-analysis of all the atrial fibrillation trials confirmed this pattern: factor XI inhibitors significantly reduced major and minor bleeding compared to DOACs but were associated with about a threefold increase in ischemic stroke risk.¹⁸

The failure makes biological sense in retrospect. In AF, blood stagnates in the left atrial appendage and forms large, fibrin-rich clots. These clots depend heavily on the full coagulation cascade, not just the intrinsic pathway that factor XI participates in. The extrinsic pathway, triggered by tissue factor, likely drives much of AF-related clot formation, and factor XI inhibitors do not block that route. The lesson is that factor XI’s contribution to clotting varies by clinical context: it matters more for some types of clots than others.

Kidney Disease and Dialysis

People on hemodialysis face an unusual problem: they are at extremely high risk of both blood clots and bleeding. Standard anticoagulants are difficult to use in this population because the drugs accumulate unpredictably and the patients’ vessels are fragile. Factor XI inhibitors have been tested here, and the results, while still early, are noteworthy.

A phase 2 trial of osocimab, a monoclonal antibody targeting factor XIa, in hemodialysis patients found that the drug did not increase clinically relevant bleeding compared with placebo. Even among the small number of patients who underwent major surgery or kidney transplantation while on osocimab, no bleeding events were reported.¹⁹ Fesomersen, the antisense approach, showed a similar safety profile in a separate phase 2 trial: bleeding rates across all three fesomersen dose groups were comparable to placebo.²⁰ A meta-analysis of the available hemodialysis data concluded that current evidence does not suggest a significantly increased bleeding risk, but whether these drugs actually reduce clot-related events in dialysis patients remains to be tested in larger trials.²¹

Medical Devices and Artificial Surfaces

Mechanical heart valves, ventricular assist devices, ECMO circuits, and dialysis tubing all share a problem: when blood contacts artificial surfaces, it triggers the contact pathway of coagulation, the same pathway that factor XI sits in. This surface-triggered clotting is a major reason patients with these devices need aggressive anticoagulation, and it is precisely the kind of clotting that factor XI inhibitors are theoretically best suited to prevent.²²

Preclinical and early clinical data suggest that targeting factor XI or factor XII can reduce device-related clotting without the hemostatic penalty of standard anticoagulants, and may also reduce the systemic inflammation that artificial surfaces provoke.²³ This is still early-stage work, but it could be one of the most transformative applications if the results hold up. Patients on long-term mechanical support currently face a grim choice between the risk of device clotting and the risk of life-threatening bleeds on warfarin.

Practical Challenges in the Clinic

Even if factor XI inhibitors prove effective in their target indications, two practical problems could complicate their everyday use: monitoring and reversal.

Standard clotting tests like the activated partial thromboplastin time (aPTT) are affected by factor XI inhibitors, but in unpredictable ways. The degree of aPTT prolongation varies depending on which reagent the lab uses, and there is no established way to translate a given aPTT number into how much anticoagulation a patient actually has. Measuring factor XI clotting activity directly is relevant only for patients on the antisense drug fesomersen (which lowers factor XI protein levels) and does not accurately reflect the effect of the small molecules or antibodies. More specialized assays exist but are not available in most hospital labs.²⁴ The small-molecule inhibitors asundexian and milvexian also interfere with a range of routine coagulation assays, producing artificially abnormal results for tests measuring other clotting factors, though charcoal-based adsorbents can strip the drugs out of a blood sample before testing.²⁵

Reversal is the other headache. If a patient on a factor XI inhibitor starts bleeding dangerously or needs emergency surgery, clinicians need a way to restore normal clotting quickly. For the antisense drug fesomersen, factor XI concentrate can replenish what the drug has depleted. For the antibodies and small molecules, which block the protein rather than eliminate it, bypassing agents like recombinant activated factor VII are the current theoretical option, though evidence for these strategies comes largely from case series and expert opinion rather than controlled trials. Tranexamic acid, an antifibrinolytic drug, has also been proposed as part of the reversal toolkit. All of these options carry their own risks, including the possibility of triggering the very clots the patient was taking the drug to prevent.²⁶ Management strategies remain provisional and will need refinement as more patients enter trials and more real-world experience accumulates.²⁷

Factor XI and Inflammation

One of the more intriguing threads in this field goes beyond clotting. Factor XI does not just promote thrombosis; it also appears to amplify inflammation. In a mouse model of severe abdominal infection, blocking factor XI activation with an antibody cut circulating levels of key inflammatory molecules by more than half and improved survival.²⁸ This connection between clotting and inflammation is not unique to factor XI, but the degree to which factor XI contributes to inflammatory cascades in humans is still being worked out. If the anti-inflammatory effects translate to people, it could expand the rationale for factor XI inhibition beyond traditional anticoagulant indications and into areas like sepsis or chronic inflammatory vascular disease.

How Factor XI Evolved

Factor XI exists because of a gene duplication event deep in mammalian history. The gene encoding factor XI, F11, arose when the gene for a related protein called prekallikrein duplicated. For years, researchers thought this duplication happened relatively recently in evolutionary terms, after marsupials split from the egg-laying monotremes like the platypus. That conclusion was based on the fact that the platypus genome assembly at the time was incomplete and appeared to lack a separate F11 gene.²⁹

More recent work with improved genome assemblies corrected this picture. Distinct F11 genes were identified in both the platypus and the short-beaked echidna, meaning the duplication happened earlier than originally thought, either in a monotreme ancestor or in a proto-mammalian lineage. The gene is absent in amphibians, reptiles, and birds, so it remains a mammalian innovation.³⁰ This means factor XI has been part of the mammalian coagulation system for well over 100 million years, yet its role in hemostasis has remained secondary to other clotting factors throughout that span. It is a protein that evolution kept around for reasons we are still untangling, and that ambiguous evolutionary role may be exactly why it turns out to be safe to inhibit.